A new industry analysis highlights how revised EU manufacturing guidelines are pushing drug developers toward stronger in-process assurance for sterile filtration. The focus is on PUPSIT (pre-use post-sterilization integrity testing), which verifies filter integrity after sterilization but before product exposure. The report’s discussion, citing Cytiva scientist Martin Glanz, notes that conventional post-use checks can miss defects masked by fouling or plugging. PUPSIT requires added operational steps—wetting, venting, and integrity testing—but aims to close that verification gap. The adoption signal matters for CMC teams because EU GMP Annex 1 revisions and broader expectations via PIC/S are changing what regulators and contract manufacturers treat as the default sterility assurance approach.